What is ABOS's market cap?

$15.46M, based on the Nov 5 close of $0.21.

Does Acumen Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ABOS is sold short?

3.1M shares, 7.6% of float, as of Oct 15, 2026.

What sector is ABOS in?

Healthcare, in the Biotechnology industry.

NASDAQ · ABOSHealthcareBiotechnology

Acumen Pharmaceuticals, Inc. Common Stock (ABOS)

$0.2138−1.16%

Close Nov 5, 2026 · split-adjusted

Nov 5, 2026$0.21▼ 89.16% in range

Nov 4, 2025Low $0.21 · High $3.37Nov 5, 2026

What changed · written from our data

As of Nov 5, 2026

Acumen Pharmaceuticals closed at $0.21 on Nov 5, down 1.16%, within 1.8% of its 52-week closing low. Volume of 6.2M shares was 0.96× its 20-day average (close to normal).

Split-adjusted performance: -89.8% over one month, -91.3% over six months, -89.0% over one year.

Short interest was 3.1M shares at the Oct 15 settlement (7.6% of float, 5.4 days to cover).

Market cap$15.5M72.3M shares

Revenue · quarter$0.00—

Diluted EPS$-0.35—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range0.21 – 3.37−93.7% from high

Volume6.2M0.96× 20-day avg

Volatility · 60d492.8%Annualised

Short % of float7.6%5.4 days to cover

Net cash$52.3MCash $78.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −90.7%1M −89.8%3M −91.2%6M −91.3%YTD −89.9%1Y −89.0%3Y −88.6%5Y −98.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum2

Revenue growth—

Net margin—

Value (low P/E)—

Size13

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →

Shares short3.1M+0.4% vs prior

Days to cover5.4Settled Oct 15

% of float7.6%

Short vol. 10d55.7%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ABOSAcumen Pharmaceuticals	$0.2138	−1.16%	−91.3%	—	—	—	$15.5M
JSPRJasper Therapeutics	$0.4692	−8.20%	−48.3%	—	—	—	$15.6M	Compare
ATYRaTyr Pharma	$6.03	−2.43%	−83.6%	—	—	—	$15.1M	Compare
PLURPluri	$1.19	−3.26%	−64.4%	−15.8%	−1755.2%	—	$16.1M	Compare
DYAIDyadic International	$0.3401	−7.25%	−54.3%	−0.6%	−221.0%	—	$13.6M	Compare
BCDABioCardia	$0.8900	−2.53%	−18.3%	—	—	—	$13.5M	Compare
ESLAEstrella Immunopharma	$0.4101	−7.53%	−67.7%	—	—	—	$17.8M	Compare
BKHABlack Hawk Acquisition	$4.50	−19.21%	—	—	—	—	$18.7M	Compare
TCRXTScan Therapeutics	$0.1818	−13.43%	−85.0%	−65.8%	−2888.6%	—	$12.3M	Compare

News about Acumen Pharmaceuticals

All news →

Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 1d ago▲ Positive Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 26, 2026▲ Positive Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026GlobeNewswire Inc. · Sep 10, 2026▲ Positive Acumen Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · Sep 2, 2026▲ Positive Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business HighlightsGlobeNewswire Inc. · May 12, 2026▲ Positive

Quick answers

What does Acumen Pharmaceuticals do?: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
What is ABOS's market cap?: $15.46M, based on the Nov 5 close of $0.21.
Does Acumen Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ABOS is sold short?: 3.1M shares, 7.6% of float, as of Oct 15, 2026.
What sector is ABOS in?: Healthcare, in the Biotechnology industry.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

HQ: Newton, MA61 employeesListed Jul 1, 2021acumenpharm.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology